Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
Liu H, Yan R, Xiao Z, Huang X, Yao J, Liu J, An G, Ge Y. Breast Cancer Res. 2023 Apr 17; 25(1):43. Epub 2023 Apr 17.